Spots Global Cancer Trial Database for brca
Every month we try and update this database with for brca cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | NCT02042378 | Pancreatic Canc... Pancreatic Duct... | Rucaparib | 18 Years - | pharmaand GmbH | |
| HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | NCT01494662 | Breast Cancer | HKI-272 Surgical Resect... Capecitabine HKI-272 Ado-Trastuzumab... | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers | NCT02321228 | BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Cancer | Salpingectomy w... Risk-reducing s... | 25 Years - 45 Years | University Medical Center Nijmegen | |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | NCT04503265 | Advanced Malign... Breast Cancer Ovarian Cancer Homologous Reco... Prostate Cancer Pancreatic Canc... | AMXI-5001:Dose ... AMXI-5001:Dose ... | 18 Years - | AtlasMedx, Incorporated | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| OSCA - Olaparib Standard of CAre Study | NCT02262273 | Platinum-sensit... | Data Collection | 18 Years - | AstraZeneca | |
| Olaparib in People With Malignant Mesothelioma | NCT03531840 | Mesothelioma | Olaparib ClinOmics | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Olaparib in People With Malignant Mesothelioma | NCT03531840 | Mesothelioma | Olaparib ClinOmics | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation | NCT04368442 | Breast Cancer M... | 20 Years - | Samsung Medical Center | ||
| Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer | NCT03205761 | Advanced Breast... | Olaparib | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation | NCT04368442 | Breast Cancer M... | 20 Years - | Samsung Medical Center | ||
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | NCT02354586 | Ovarian Neoplas... Ovarian Cancer | Niraparib | 18 Years - | Tesaro, Inc. | |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | NCT01905592 | Neoplasms, Brea... Carcinoma of Br... Human Epidermal... BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Neoplas... | niraparib Physician's cho... | 18 Years - | Tesaro, Inc. | |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | NCT02000622 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | Olaparib Physician's cho... | 18 Years - 99 Years | AstraZeneca | |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | NCT01874353 | Platinum Sensit... BRCA Mutated Relapsed Ovaria... Following Compl... | Olaparib 300mg ... Placebo to matc... | 18 Years - 130 Years | AstraZeneca | |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | NCT01844986 | Newly Diagnosed Advanced Ovaria... FIGO Stage III-... BRCA Mutation Complete Respon... Partial Respons... First Line Plat... | Olaparib 300mg ... | 18 Years - 130 Years | AstraZeneca | |
| A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | NCT02950064 | Pancreatic Neop... Ovarian Neoplas... Breast Neoplasm... Prostatic Neopl... | BTP-114 | 18 Years - | Placon Therapeutics | |
| Safety of Pregnancy in BRCA Mutated Breast Cancer Patients | NCT03673306 | Breast Cancer | Clinical outcom... | 18 Years - 40 Years | Jules Bordet Institute | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency | NCT04892693 | Advanced Breast... | Talazoparib Ora... | 19 Years - | Seoul National University Hospital | |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | NCT02571725 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Olaparib Tremelimumab | 18 Years - | New Mexico Cancer Care Alliance | |
| CBPR - BRCA Genetic Testing Among Orthodox Jews | NCT03624088 | Breast Cancer | RealRisks | 25 Years - | Columbia University | |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | NCT02571725 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Olaparib Tremelimumab | 18 Years - | New Mexico Cancer Care Alliance | |
| A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | NCT01847274 | Ovarian Neoplas... Platinum Sensit... | Active comparat... placebo | 18 Years - | Tesaro, Inc. | |
| Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02470585 | Ovarian Cancer Ovarian Neoplas... | Veliparib Paclitaxel Carboplatin Placebo to Veli... | 18 Years - | AbbVie | |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | NCT02000622 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | Olaparib Physician's cho... | 18 Years - 99 Years | AstraZeneca | |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | NCT02354586 | Ovarian Neoplas... Ovarian Cancer | Niraparib | 18 Years - | Tesaro, Inc. | |
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | NCT02000622 | Breast Cancer M... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | Olaparib Physician's cho... | 18 Years - 99 Years | AstraZeneca | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| Olaparib in People With Malignant Mesothelioma | NCT03531840 | Mesothelioma | Olaparib ClinOmics | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
